Copper-67-labeled bombesin peptide for targeted radionuclide therapy of prostate cancer

Authors

Truc T Huynh, Washington University School of Medicine in St. Louis
Ellen M van Dam, Clarity Pharmaceuticals Ltd.
Sreeja Sreekumar, Washington University School of Medicine in St. Louis
Cedric Mpoy, Washington University School of Medicine in St. Louis
Benjamin J Blyth, Peter MacCallum Cancer Centre
Fenella Muntz, Peter MacCallum Cancer Centre
Matthew J Harris, Clarity Pharmaceuticals Ltd.
Buck E Rogers, Washington University School of Medicine in St. Louis

Journal

Pharmaceuticals (Basel)

Publication Date

6-8-2022

Volume

15

Issue

6

First Page

728

Document Type

Open Access Publication

DOI

10.3390/ph15060728

Rights and Permissions

Huynh, T.T.; van Dam, E.M.; Sreekumar, S.; Mpoy, C.; Blyth, B.J.; Muntz, F.; Harris, M.J.; Rogers, B.E. Copper-67-Labeled Bombesin Peptide for Targeted Radionuclide Therapy of Prostate Cancer. Pharmaceuticals 2022, 15, 728. https://doi.org/10.3390/ph15060728 This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited

Recommended Citation

Huynh, Truc T; van Dam, Ellen M; Sreekumar, Sreeja; Mpoy, Cedric; Blyth, Benjamin J; Muntz, Fenella; Harris, Matthew J; and Rogers, Buck E, "Copper-67-labeled bombesin peptide for targeted radionuclide therapy of prostate cancer." Pharmaceuticals (Basel). 15, 6. 728 (2022).
https://digitalcommons.wustl.edu/oa_3/60